Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC joint panel planned

This article was originally published in The Tan Sheet

Executive Summary

FDA's drug center has tentatively scheduled a joint meeting of its Endocrinologic and Metabolic Drugs Advisory Committee and its Nonprescription Drugs Advisory Committee for Dec. 13 and 14. The agency will not discuss the planned topic until publishing a Federal Register notice announcing a confirmed meeting. Previously, the agency convened the same joint panel to consider the suitability of statins, including Merck's Mevacor (lovastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) for OTC sale, and to review GlaxoSmithKline's weight-loss drug alli (orlistat) for an Rx-to-OTC switch. Bayer, which now holds the OTC rights for Pravachol, is pursuing an active program to switch the drug to OTC, while J&J/Merck is still seeking a switch for Mevacor (1"The Tan Sheet" July 2, 2007, In Brief)...

You may also be interested in...



Pravastatin Reduces Mortality 10 Years After Use – Study

Results of a follow-up primary prevention trial finding treatment with pravastatin provided ongoing cardiac event risk reduction 10 years later could strengthen the case for OTC statins

Bayer Pravachol switch program still alive

Bayer HealthCare is "working with the FDA" on its planned Rx-to-OTC switch of Bristol-Myers Squibb's cholesterol drug, Pravachol, Gary Balkema, the firm's Consumer Care Division president, says June 19. During Bayer's investor conference in Leverkusen, Germany, Balkema said gaining FDA approval for low-dose Pravachol is the division's top switch priority. "Companies that have the ability to introduce switches see some significant growth opportunities and we plan to be one of those companies," he said, adding Bayer will "explore additional switch opportunity projects." Bayer acquired U.S. marketing rights for a switch of the statin in 2004 (1"The Tan Sheet" Dec. 13, 2004, p. 5). An advisory panel review would be the second time around for pravastatin, which went before a joint panel in 2000 and failed to gain approval from the agency, as did Merck's Mevacor (lovastatin). The agency's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees again voted against J&J and Merck's switch proposal for Mevacor in 2005 (2"The Tan Sheet" Jan. 17, 2005, p. 3). Following the vote, Merck has worked with FDA on labeling to be tested for an OTC Mevacor and on testing methodologies (3"The Tan Sheet" March 20, 2006, p. 4)...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS100912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel